Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW3811 in pathological scars (Phase II, randomized, double-blind, placebo-controlled)
CTR20254857Phase 2Active
- Sponsor
- Maiwei Biotech
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 9MW3811 in Pathological scar, sponsored by Maiwei Biotech. Started Dec 2025; status: active.
02
Drugs
9MW3811
03
Conditions
Pathological scar
Beyond the preview
Go deeper on CTR20254857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254857.